and Juneau et al., the severity of endometriosis was not clarified, and without laparoscopic confirmation, the control groups may have included a number of patients with endometriosis
If transferring peptides to different containers becomes necessary, use appropriate sterile vials designed for pharmaceutical storage
The release data of SA and bioavailable silicon from MSNs-ss-SA were analyzed using zero-order (2), first-order (3), Higuchi (4), Ritger-Peppas (5), and Weibull (6) models, respectively [48]: where M t is the amount of SA or bioavailable silicon released at time t
Alternative (3/week): Consistent 2.0 mg per injection for simplified scheduling
The peptides extended half-life (~68 days) supports weekly administration without significant loss of activity between doses [1]
This conservative starting point allows assessment of individual response before increasing